Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.67 |
| ▸ | MTOR | P42345 | 14/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.57 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.57 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.57 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.57 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.57 |
| ▸ | PRKDC | P78527 | 3/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | HCK | P08631 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150471 | 0.92 | MTOR (0.58) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL30405455 | 0.88 | MTOR (0.60) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL31046944 | 0.88 | MTOR (0.60) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL20553461 | 0.88 | MTOR (0.60) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL25064728 | 0.88 | MTOR (0.62) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL30405094 | 0.86 | SRC (0.58) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL24519546 | 0.84 | MTOR (0.57) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL23251634 | 0.84 | MTOR (0.59) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL23251883 | 0.84 | MTOR (0.59) | SRCMTORPIK3CDPIK3CAPIK3CG | |
| SCHEMBL23251522 | 0.84 | MTOR (0.57) | SRCMTORPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3153023-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010051043-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051042-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SRC 68/4885MTOR 2/4885PIK3CD 13/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | SRC 1374/4885MTOR 2/4885PIK3CD 150/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SRC 68/4885MTOR 2/4885PIK3CD 13/4885 |
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | SRC 825/4885MTOR 424/4885PIK3CD 446/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | SRC 1515/4885MTOR 3565/4885PIK3CD 2330/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | SRC 248/4885MTOR 1/4885PIK3CD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.